News
Bioiberica’s joint healthcare division and heparin business unit participated at the CPhl Russia fair, one of the most important events for the pharmaceutical sector
The Russian pharmaceutical market is growing at a 10 percent annual rate, and is expected to reach 25 Billion Dollars by 2018
Our company was granted “good” qualification within the A Group, the one formed by companies having their own manufacturing and R&D center in Spain
- The company is boosting its online communication with the goal of making it more active and offering high-value content for the target public of its activity sectors (human, animal and plant health)
- The new, highly visual website design adapts to mobile devices (responsive design) and makes interaction easier
This certification is a recognition of the excellence standards achieved by Bioiberica in their effort to improve energy efficiencyDuring the next three years, our company has set the following objectives: 15% reduction in energy consumption per production unit, 10% of the energy will come from by-product use, and 5% from renewable energies
Bioiberica has been assigned to the A group, which corresponds to companies having their own R&D center and production plant, with a significant volume of research.The biotech company invests close to13% of its profits into R&D, and during 2013 they intend to begin marketing their personalized medicine range of products for osteoarthritis treatment.